Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. [clinicaltrials:NCT00002147]
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. [clinicaltrials:NCT00002147]
Bio2RDF identifier
NCT00002147
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00002147
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
To provide Stealth lipo ...... thout an
anthracycline.
brief title [clinicaltrials_vocabulary:brief-title]
Use of Stealth Liposomal Doxor ...... AIDS-Related Kaposi's Sarcoma.
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Patients receive DOX-SL every 3 weeks for up to 20 cycles.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Acquired Immunodeficiency Syndrome
Doxorubicin
Drug Carriers
Sarcoma, Kaposi
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2005-06-23T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00002147
official title [clinicaltrials_vocabulary:official-title]
Use of Stealth Liposomal Doxor ...... AIDS-Related Kaposi's Sarcoma.
org study id [clinicaltrials_vocabulary:org-study-id]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
1996-01-01T00:00:00Z
identifier
clinicaltrials:NCT00002147
title
Use of Stealth Liposomal Doxor ...... AIDS-Related Kaposi's Sarcoma.
@en
type
label
Use of Stealth Liposomal Doxor ...... . [clinicaltrials:NCT00002147]
@en